Use of Bone Health Protocol to Identify and Prevent Bone Disease in Kidney and Pancreas Transplant Recipients

Author:

Taber David J1,Ashcraft Elizabeth A2,Baillie G Mark3,Lawrence D Bart4,Chavin Kenneth D5,Baliga Prabhakar K6

Affiliation:

1. David J Taber PharmD BCPS, Clinical Pharmacy Specialist, Medical University of South Carolina, Charleston, SC

2. Elizabeth A Ashcraft PharmD, Clinical Pharmacy Specialist, Medical University of South Carolina

3. G Mark Baillie PharmD, Clinical Pharmacy Specialist, Medical University of South Carolina

4. D Bart Lawrence PharmD, Medical Science Liaison, Pfizer Global Pharmaceuticals, New York, NY

5. Kenneth D Chavin MD PhD, Associate Professor of Surgery, Department of Surgery, Division of Transplant, Medical University of South Carolina

6. Prabhakar K Baliga MD, Director, Division of Transplant Surgery; Professor of Surgery, Department of Surgery, Division of Transplant, Medical University of South Carolina

Abstract

BACKGROUND: Posttransplant bone disease is a well recognized and under-treated problem. The use of protocols within other populations has been shown to improve recognition and treatment of common disease states, but outcome studies involving the use of protocols within transplant patients are lacking. OBJECTIVE: To compare the appropriate screening for and the prevention and treatment of osteopenia and osteoporosis in transplant patients before and after a bone health protocol was implemented. METHODS: A retrospective analysis in a single institution was designed to determine whether the development and implementation of a comprehensive bone health protocol impacted disease outcomes in posttransplant kidney and simultaneous kidney—pancreas patients. RESULTS: There were 132 patients in the historical control group and 76 in the treatment group. The groups were well matched, with no statistically significant differences noted for any of the baseline characteristics that were compared, including the modifiable and nonmodifiable risk factors known to put a patient at increased risk for osteopenia or osteoporosis. Significantly more patients in the treatment group received proper screening and prevention compared with the historical control group (p < 0.001). Although more patients in the treatment group received proper bone disease treatment, this did not reach statistical significance (81% vs 66%; p < 0.22). Additionally, the dual energy X-ray absorptiometry scans were performed, on average, 19 days earlier in the treatment group, although this also did not achieve statistical significance (p = 0.149). CONCLUSIONS: The multidisciplinary development and implementation of a comprehensive bone health protocol improves the screening and prevention of osteopenia and osteoporosis within kidney and pancreas transplant recipients. TRASFONDO: La enfermedad ósea luego de un transplante de órganos es un problema conocido y que no es tratado adecuadamente. La utilización de protocolos en otras poblaciones ha demostrado mejorar el reconocimiento y tratamiento de enfermedades comunes pero no hay suficientes estudios de los resultados del uso de protocolos en pacientes con transplante de órganos.

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3